COPENHAGEN, DenmarkNovember 9, 2022 – Bavarian Nordic A/S BAVA today announced its preliminary financial results for the first nine months of 2022 and business development for the third quarter of 2022.
Paul Chaplin, President & Chief Executive Officer of Bavarian Nordic said: “These are exciting times for Bavarian Nordic as we have continued to expand our activities in support of the global response to monkeypox while conducting two global Phase 3 studies with our late-stage pipeline assets. We are very encouraged to see how our vaccines are working and can really make a difference by bringing comfort to vulnerable populations and helping to change the trajectory of the monkeypox outbreak. More than 1 million people have received our vaccine since the outbreak began and the number is growing by the day and we have already secured important orders for 2023 and beyond. Deliveries have been ramped up over the last 3 months and will continue into fourth quarter continued as we expand shipments of our smallpox/monkeypox vaccine to more than 70 countries worldwide Increased sales of our products across our portfolio are driving consistently strong sales and we are nearing an EBITDA break-even for 2022. “
Financial highlights
- Total revenue for the first nine months was DKK 1,860m, of which DKK 1,752m came from product sales, DKK 83m from milestone payments from partners and DKK 25m from commissioned work.
- Third quarter sales amounted to 1,004 million DKK and included…
